Tagged with OP

USA David H. Crean, PhD, Managing Director for Objective Capital Partners, a leading investment banking advisory firm examines the healthcare market for 2018.     Following a decade high of VC invested in 2017, and on a record pace again in 2018, valuations continue to move higher across all stages within…

UK Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In his second piece for PharmaBoardroom, Aditya examines the dangers of nationalism and populism for the private sector.   The biggest global risk I see is with active pharmaceutical ingredients, most of which come from China, which has been at the centre of trade tensions,…

Innovation Buck Dossey, an expert in digital marketing and audience manager at Adobe, discusses consumer needs in healthcare and the importance of adopting a digital health strategy.  Joining the digital transformation race today means that many companies will have to transform to become digitally agile.  While the topic of digital transformation permeates…

UK With more than 25 years pharmaceutical industry experience, Ian Chamberlain provides training to help pharma salespeople talk to customers and provides sales managers with software to help pharma companies intelligently listen to the dialogue. As an insider, Ian breaks down the changing role of medical salespeople, from “Tell Sell” to “Intelligent…

Europe The latest EFPIA data ranking European countries by the value of their pharmaceutical production. Switzerland is far and away the leader by this measurement, with EUR 46.280 billion-worth of pharma production in 2016, followed by Italy and Germany.

Mexico Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine. Here he discusses the new Alma-Ata Declaration that focuses on primary care and work at…

Canada Mark Ware, the Chief Medical Officer of Canopy Growth Corporation, has intensely investigated the effects of cannabinoids, making him perfectly placed to cover this new era of cannabis in healthcare.    I propose that the renaissance of cannabis under varying regulatory frameworks actually represents a paradigm shift in health care, and…

Regulation Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the United States, discusses the contradictory nature of Trump’s efforts to lower drug prices.    The President has forcefully pledged to provide relief to these patients and their families, but his own trade policy threatens…

Innovation Patient groups oftentimes serve as the authority on a specific disease when it comes to advancing research.   “Without patient perspective, there is no good medical product development,” Rachel Sherman, the FDA’s principal deputy commissioner proclaimed during her keynote at last week’s NORD’s Rare Disease & Orphan Products Breakthrough Summit.…

Mexico David Peña Castillo is the President and founder of The Mexican Federation of Rare Diseases (FEMEXER). Here he discusses what makes a patients association. When we find a way to communicate the complexities of rare diseases simply, we can avoid isolating anyone and the potential to uncover important information is…

Kazakhstan Following the initiative of the Ministry of Health, Kazakhstan engaged in activities to reform its healthcare legislation. The concept of the updated Kazakhstan Code “On People’s Health and Healthcare System” is expected to be proposed for consideration by the countries Government in December 2018 and by their Parliament in the…

USA After her son was diagnosed with SYNGAP1 – an extremely rare gene mutation – Monica founded Bridge the Gap – SYNGAP Education and Research Foundation to support families of those suffering from the illness and to accelerate the path to better therapies. Here she discusses the importance of community for tackling rare…